Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/34699
Full metadata record
DC FieldValueLanguage
dc.date.accessioned2023-10-31T12:17:49Z-
dc.date.available2023-10-31T12:17:49Z-
dc.date.issued2018-08-
dc.identifier.citationDalkılıç, E. vd. (2018). ''Methotrexate intoxication: Beyond the adverse events''. International Journal of Rheumatic Diseases, 21(8), 1557-1562.en_US
dc.identifier.issn1756-1841-
dc.identifier.issn1756-185X-
dc.identifier.urihttps://doi.org/10.1111/1756-185X.13339-
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/10.1111/1756-185X.13339-
dc.identifier.urihttp://hdl.handle.net/11452/34699-
dc.description.abstractAim: Methotrexate (MTX) is the first-line disease-modifying antirheumatic drug in rheumatoid arthritis (RA). However, this anchor may cause some side effects that may range from nausea to mortality. The clinical features of MTX toxicity are under-researched. In this study, we aimed to find out the potential predisposing factors and outcomes of the MTX toxicity (n = 31). Methods: The data were collected from 31 patients whose ages ranged from 25 to 81 years, who were suffering from immune-mediated inflammatory diseases and major MTX-related toxicity. Results: Out of 31 patients, six (19.4%) used MTX every day, and 13 (41.9%) patients had renal insufficiency who were admitted to the hospital because of mucositis (90.3%) and fever (71%). While using MTX, 27 patients (87.1%) were discharged after the treatment and four patients (12.9%) died. Conclusions: Although MTX has high efficacy for the toxicity ratio, wrong use and dosage of MTX may be harmful to patients. Thus, patients should be informed about the proper use of MTX.en_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectRheumatologyen_US
dc.subjectMethotrexateen_US
dc.subjectMethotrexate toxicityen_US
dc.subjectRenal insufficiencyen_US
dc.subjectLow-dose methotrexateen_US
dc.subjectRheumatoid-arthritisen_US
dc.subjectAcid supplementationen_US
dc.subjectInduced pancytopeniaen_US
dc.subjectFolinic aciden_US
dc.subjectToxicityen_US
dc.subjectTherapyen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 and overen_US
dc.subject.meshAntirheumatic agentsen_US
dc.subject.meshArthritis, rheumatoiden_US
dc.subject.meshCommunicable diseasesen_US
dc.subject.meshDose-response relationship, drugen_US
dc.subject.meshDrug interactionsen_US
dc.subject.meshFemaleen_US
dc.subject.meshFeveren_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMedication errorsen_US
dc.subject.meshMethotrexateen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshMucositisen_US
dc.subject.meshPurpura, thrombocytopenicen_US
dc.subject.meshRenal insufficiencyen_US
dc.subject.meshRetrospective studiesen_US
dc.subject.meshRisk assessmenten_US
dc.subject.meshRisk factorsen_US
dc.subject.meshTurkeyen_US
dc.titleMethotrexate intoxication: Beyond the adverse eventsen_US
dc.typeArticleen_US
dc.identifier.wos000442740000011tr_TR
dc.identifier.scopus2-s2.0-85052205923tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0003-0298-4157tr_TR
dc.identifier.startpage1557tr_TR
dc.identifier.endpage1562tr_TR
dc.identifier.volume21tr_TR
dc.identifier.issue8tr_TR
dc.relation.journalInternational Journal of Rheumatic Diseasesen_US
dc.contributor.buuauthorDalkılıç, Ediz-
dc.contributor.buuauthorCoşkun, Belkıs Nihan-
dc.contributor.buuauthorYağız, Burcu-
dc.contributor.buuauthorTufan, Ayşe Nur-
dc.contributor.buuauthorErmurat, Selime-
dc.contributor.buuauthorPehlivan, Yavuz-
dc.contributor.researcheridAAG-7155-2021tr_TR
dc.contributor.researcheridABE-4424-2022tr_TR
dc.contributor.researcheridAAG-8227-2021tr_TR
dc.identifier.pubmed30146743tr_TR
dc.subject.wosRheumatologyen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.indexed.pubmedPubMeden_US
dc.wos.quartileQ4en_US
dc.contributor.scopusid6506739457tr_TR
dc.contributor.scopusid55646165400tr_TR
dc.contributor.scopusid57203458191tr_TR
dc.contributor.scopusid56076552900tr_TR
dc.contributor.scopusid55371331300tr_TR
dc.contributor.scopusid13205593600tr_TR
dc.subject.scopusMethotrexate; Rheumatoid Arthritis; Pustulosis Palmoplantarisen_US
dc.subject.emtreeAcemetacinen_US
dc.subject.emtreeAcetylsalicylic aciden_US
dc.subject.emtreeAntibiotic agenten_US
dc.subject.emtreeDiclofenacen_US
dc.subject.emtreeFilgrastimen_US
dc.subject.emtreeFolinate calciumen_US
dc.subject.emtreeIbuprofenen_US
dc.subject.emtreeIndometacinen_US
dc.subject.emtreeMethotrexateen_US
dc.subject.emtreeNonsteroid antiinflammatory agenten_US
dc.subject.emtreeOmeprazoleen_US
dc.subject.emtreeRamiprilen_US
dc.subject.emtreeAntirheumatic agenten_US
dc.subject.emtreeMethotrexateen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeClinical articleen_US
dc.subject.emtreeCoughingen_US
dc.subject.emtreeDeathen_US
dc.subject.emtreeDisease predispositionen_US
dc.subject.emtreeDose calculationen_US
dc.subject.emtreeDrug efficacyen_US
dc.subject.emtreeDrug informationen_US
dc.subject.emtreeDrug intoxicationen_US
dc.subject.emtreeDrug megadoseen_US
dc.subject.emtreeDrug misuseen_US
dc.subject.emtreeDrug potentiationen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeFeveren_US
dc.subject.emtreeHeadacheen_US
dc.subject.emtreeHospital admissionen_US
dc.subject.emtreeHospital dischargeen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeInfectionen_US
dc.subject.emtreeInflammatory diseaseen_US
dc.subject.emtreeKidney failureen_US
dc.subject.emtreeLongitudinal studyen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeMiddle ageden_US
dc.subject.emtreeMucosa inflammationen_US
dc.subject.emtreeMycosis fungoidesen_US
dc.subject.emtreeNauseaen_US
dc.subject.emtreeOpen studyen_US
dc.subject.emtreeOutcome assessmenten_US
dc.subject.emtreePatient risken_US
dc.subject.emtreePneumoniaen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreePsoriatic arthritisen_US
dc.subject.emtreePurpuraen_US
dc.subject.emtreeRetrospective studyen_US
dc.subject.emtreeRheumatoid arthritisen_US
dc.subject.emtreeSjoegren syndromeen_US
dc.subject.emtreeSystemic sclerosisen_US
dc.subject.emtreeTurkey (republic)en_US
dc.subject.emtreeVery elderlyen_US
dc.subject.emtreeChemically induceden_US
dc.subject.emtreeCommunicable diseaseen_US
dc.subject.emtreeDose responseen_US
dc.subject.emtreeDrug interactionen_US
dc.subject.emtreeFeveren_US
dc.subject.emtreeKidney failureen_US
dc.subject.emtreeMedication erroren_US
dc.subject.emtreeMortalityen_US
dc.subject.emtreeMucosa inflammationen_US
dc.subject.emtreeRisk assessmenten_US
dc.subject.emtreeRisk factoren_US
dc.subject.emtreeThrombocytopenic purpuraen_US
dc.subject.emtreeTurkey (bird)en_US
Appears in Collections:Scopus
Web of Science

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.